Attenuation of the euphoric effects of cocaine by the dopamine D1/D5 antagonist ecopipam (SCH 39166)

Archives of General Psychiatry

Volumn 56, Issue 12, 1999, Pages 1101-1106

  Romach, Myroslava K ^a,f   Glue, Paul ^e   Kampman, Kyle ^d   Kaplan, Howard L ^a,c   Somer, Gail R ^a   Poole, Sabrina ^d   Clarke, Laura ^e   Coffin, Vicki ^e   Cornish, James ^d   O'Brien, Charles P ^d   Sellers, Edward M ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

^f SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COCAINE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 5 RECEPTOR; ECOPIPAM; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR RESPONSE; CLINICAL ARTICLE; CLINICAL TRIAL; COCAINE DEPENDENCE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DYSPEPSIA; EUPHORIA; FEMALE; HEADACHE; HUMAN; MALE; MESOLIMBIC DOPAMINERGIC SYSTEM; MOOD; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE;

EID: 0032735741     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.56.12.1101     Document Type: Article

References (27)

1. Woolverton WL, Johnson KM. Neurobiology of cocaine abuse. Trends Pharmacol Sci. 1992;13:193-200.
2. Koob GF, Bloom FE. Cellular and molecular mechanisms of drug dependence. Science. 1988;242:715-723.
3. Bergman J, Kamien JB, Spealman RD. Antagonism of cocaine self-administration by selective dopamine D1 and D2 antagonists, Behav Pharmacol. 1990;1:355-363.
4. Spealman RD, Bergman J, Madras BK, Melia KF. Discriminative stimulus effects of cocaine in squirrel monkeys: involvement of dopamine receptor subtypes. J Pharmacol Exp Ther. 1991;258:945-953.
5. Spealman RD. Antagonism of the behavioral effects of cocaine by selective dopamine receptor blockers. Psychopharmacology. 1990;101:142-145.
6. Caine SB, Koob GF. Effects of dopamine D1 and D2 antagonists on cocaine self-administration under different schedules of reinforcement in the rat. J Pharmacol Exp Ther. 1994;270:209-218.
7. di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A. 1988;85:5274-5278.
8. Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science. 1987;237:1219-1223.
9. Gawin FH. Cocaine addiction: psychology and neurophysiology. Science. 1991; 251:1580-1586.
10. Self DW, Barnhart WJ, Lehman DA, Nestler EJ. Opposite modulation of cocaine seeking behavior by D1-and D2-like dopamine receptor antagonists. Science. 1996;271:1586-1589.
11. Meert TF, De Haes P, Aerts N, Clincke G. Antagonism of the discriminative stimulus properties of cocaine with the combination of a dopamine D1 and D2 antagonist. Acta Neurobiol Exp. 1996;56:897-905.
12. Cervo L, Samanin R. Effects of dopaminergic and glutamatergic receptor antagonists on the acquisition and expression of cocaine conditioning place preference. Brain Res. 1995;673:242-250.
13. Neisewander JL, O'Dell LE, Redmond JC. Localization of dopamine receptor subtypes occupied by intra-accumbens antagonists that reverse cocaine-induced locomotion. Brain Res. 1995;671:210-212.
14. Xu M, Moratalla R, Gold LH, Hiroi N, Koob GF, Graybiel AM, Tonegawa S. Dopamine D1 receptor mutant mice are deficient in striatal expression of dynorphin and in dopamine-mediated behavioral responses. Cell. 1994;79:729-742.
15. Kaddis FG, Wallace LJ, Uretsky NJ. AMPA/kainate antagonists in the nucleus accumbens inhibit locomotor stimulatory response to cocaine and dopamine agonists. Pharmacol Biochem Behav. 1993;46:703-708.
16. McHugh D, Coffin VL. SCH 39166, a D1 receptor antagonist, selectively blocked a cocaine-induced increase in spontaneous locomotor activity in mice [abstract]. Soc Neurosci Abstr. 1993;19:1847.
17. Barrett-Larimore RL, Spealman RD. Reinstatement of cocaine-seeking behavior in a non-human primate model of relapse [abstract]. Soc Neurosci Abstr. 1996; 22:925.
18. Schindler CW, Tella SR, Witkin JM, Goldberg SR. Effects of cocaine alone and in combination with haloperidol and SCH 23390 on cardiovascular function in squirrel monkeys. Life Sci. 1991;48:1547-1554.
19. Johanson C-E, Fischman MW. The pharmacology of cocaine related to its abuse. Pharmacol Rev. 1989;41:3-52.
20. Fischman MW, Schuster CR, Resnekov L, Shick JF, Krasnegor NA, Fennell W, Freedman DX. Cardiovascular and subjective effects of intravenous cocaine administration in humans. Arch Gen Psychiatry. 1976;33:983-989.
21. Resnick RB, Kestenbaum RK, Schwartz LK. Acute systemic effects of cocaine in man: a controlled study by intranasal and intravenous routes. Science. 1977; 195:696-698.
22. McQuade RD, Duffy RA, Coffin VL, Chipkin RE, Barnett A. In vivo binding of SCH 39166: a D1 selective antagonist. J Pharmacol Exp Ther. 1991;257:42-49.
23. Karlsson P, Sedvall G, Halldin C, Swahn C-G, Farde L. Evaluation of SCH 39166 as PET ligand for central D1 dopamine receptor binding and occupancy in man. Psychopharmacology. 1995;121:300-308.
24. Sherer MA, Kumor KM, Jaffe JH. Effects of intravenous cocaine are partially attenuated by haloperidol. Psychiatry Res. 1989;27:117-125.
25. Berger SP, Hall S, Mickalian JD, Reid MS, Crawford CA, Delucchi K, Carr K, Hall S. Haloperidol antagonism of cue-elicited cocaine craving. Lancet. 1996;347: 504-508.
26. Rowbotham MC, Jones RT, Benowitz NL, Jacob P III. Trazodone-oral cocaine interactions. Arch Gen Psychiatry. 1984;41:895-899.
27. White FJ, Joshi A, Koeltzow TE, Hu X-T. Dopamine receptor antagonists fail to prevent induction of cocaine sensitization. Neuropsychopharmacology. 1998; 18:26-40.